Physician

Joel Scott Grossman, MD

According to 2025 Medicare claims, Joel Grossman, MD (NPI: 1699838979) practices medical oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34102-5451.

Grossman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,121 traditional Medicare patients, billed 388,219 HCPCS/CPT codes, and received $6,009,451 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,590 prescription claims across 331 beneficiaries totaling $7,084,125 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 168 records totaling $4,297. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,490,049 to $7,084,125. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $14,860 to $4,484.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,772	348,620	$4,361,437
2016	1,745	411,739	$4,886,154
2017	1,748	386,100	$4,800,895
2018	1,785	400,706	$5,625,094
2019	1,790	425,228	$5,844,693
2020	1,502	416,182	$6,113,343
2021	980	411,784	$5,885,688
2022	917	387,899	$5,226,127
2023	964	350,663	$4,656,769
2024	1,121	388,219	$6,009,451

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	179	839	$1,490,049
2016	190	1,060	$2,405,512
2017	216	1,138	$2,817,183
2018	213	1,128	$3,823,769
2019	216	1,139	$4,047,354
2020	251	1,248	$4,122,733
2021	257	1,257	$4,719,566
2022	234	1,210	$4,808,286
2023	263	1,267	$4,680,503
2024	331	1,590	$7,084,125

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	44	319	$44,840
2016	N/R	206	$18,431
2017	N/R	95	$16,906
2018	N/R	45	$4,759
2019	N/R	38	$4,154
2020	N/R	28	$1,976
2021	N/R	27	$1,641
2022	N/R	12	$151
2023	N/R	N/R	N/R
2024	N/R	12	$150

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	760	2,222	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	365	622	$66
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	337	495	$13
36415	Insertion of needle into vein for collection of blood sample	918	3,200	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	893	3,618	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	121	3,267	$1,856,395
Brukinsa	Zanubrutinib	44	1,320	$626,870
Imbruvica	Ibrutinib	39	1,108	$594,122
Kisqali	Ribociclib Succinate	37	1,036	$512,989
Pomalyst	Pomalidomide	21	588	$466,644

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	168	$4,297	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joel Scott Grossman, MD?

Tedicare shows public-source Medicare data for Joel Scott Grossman, MD (NPI 1699838979), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joel Scott Grossman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joel Scott Grossman, MD?

Joel Scott Grossman, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Joel Scott Grossman, MD have Open Payments data?

Joel Scott Grossman, MD has 168 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.